Predictors of oropharyngeal cancer survival in Europe

D. Anantharaman, A. Billot, T. Waterboer, T. Gheit, B. Abedi-Ardekani, P. Lagiou, A. Lagiou, W. Ahrens, I. Holcátová, F. Merletti, K. Kjaerheim, J. Polesel, L. Simonato, L. Alemany, M. Mena Cervigon, T. V. Macfarlane, A. Znaor, P. J. Thomson, M. Robinson, C. CanovaD. I. Conway, S. Wright, C. M. Healy, M. E. Toner, M. Pawlita, M. Tommasino, P. Brennan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: HPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative patients. Currently, strategies for treatment de-escalation are based on HPV status, smoking history and disease stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in OPC survival remains uncertain. Materials and Methods: We examined factors associated with OPC outcome in 321 patients recruited in a large European multi-center study. Seropositivity for HPV16 E6 was used as a marker of HPV16 positive cancer. Hazard ratios (HR) and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential confounders. Results: Overall 5-year survival following OPC diagnosis was 50%. HPV16-positive OPC cases were at significantly lower risk of death (aHR = 0.51, 95% CI: 0.32–0.80). A significant effect on OPC survival was apparent for female sex (aHR 0.50: 95% CI: 0.29–0.85) and being underweight at diagnosis (aHR: 2.41, 95% CI: 1.38–4.21). A 10 pack year smoking history was not associated with overall survival. Higher stage at diagnosis appeared as the only factor significantly associated with OPC recurrence (aHR: 4.88, 95% CI: 2.12–11.21). Conclusion: This study confirms that HPV16 status is an independent prognostic factor for OPC survival while female sex lowers risk of death and being underweight at diagnosis increases the risk of death. Smoking was not an independent predictor of OPC survival.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalOral Oncology
Volume81
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Oropharyngeal Neoplasms
Survival
Confidence Intervals
Smoking
Thinness
History
Proportional Hazards Models
Recurrence

Keywords

  • Body mass index
  • Gender
  • Head and neck cancer
  • HPV16
  • Oropharynx cancer
  • Survival
  • Tobacco

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Anantharaman, D., Billot, A., Waterboer, T., Gheit, T., Abedi-Ardekani, B., Lagiou, P., ... Brennan, P. (2018). Predictors of oropharyngeal cancer survival in Europe. Oral Oncology, 81, 89-94. https://doi.org/10.1016/j.oraloncology.2018.04.016

Predictors of oropharyngeal cancer survival in Europe. / Anantharaman, D.; Billot, A.; Waterboer, T.; Gheit, T.; Abedi-Ardekani, B.; Lagiou, P.; Lagiou, A.; Ahrens, W.; Holcátová, I.; Merletti, F.; Kjaerheim, K.; Polesel, J.; Simonato, L.; Alemany, L.; Mena Cervigon, M.; Macfarlane, T. V.; Znaor, A.; Thomson, P. J.; Robinson, M.; Canova, C.; Conway, D. I.; Wright, S.; Healy, C. M.; Toner, M. E.; Pawlita, M.; Tommasino, M.; Brennan, P.

In: Oral Oncology, Vol. 81, 01.06.2018, p. 89-94.

Research output: Contribution to journalArticle

Anantharaman, D, Billot, A, Waterboer, T, Gheit, T, Abedi-Ardekani, B, Lagiou, P, Lagiou, A, Ahrens, W, Holcátová, I, Merletti, F, Kjaerheim, K, Polesel, J, Simonato, L, Alemany, L, Mena Cervigon, M, Macfarlane, TV, Znaor, A, Thomson, PJ, Robinson, M, Canova, C, Conway, DI, Wright, S, Healy, CM, Toner, ME, Pawlita, M, Tommasino, M & Brennan, P 2018, 'Predictors of oropharyngeal cancer survival in Europe', Oral Oncology, vol. 81, pp. 89-94. https://doi.org/10.1016/j.oraloncology.2018.04.016
Anantharaman D, Billot A, Waterboer T, Gheit T, Abedi-Ardekani B, Lagiou P et al. Predictors of oropharyngeal cancer survival in Europe. Oral Oncology. 2018 Jun 1;81:89-94. https://doi.org/10.1016/j.oraloncology.2018.04.016
Anantharaman, D. ; Billot, A. ; Waterboer, T. ; Gheit, T. ; Abedi-Ardekani, B. ; Lagiou, P. ; Lagiou, A. ; Ahrens, W. ; Holcátová, I. ; Merletti, F. ; Kjaerheim, K. ; Polesel, J. ; Simonato, L. ; Alemany, L. ; Mena Cervigon, M. ; Macfarlane, T. V. ; Znaor, A. ; Thomson, P. J. ; Robinson, M. ; Canova, C. ; Conway, D. I. ; Wright, S. ; Healy, C. M. ; Toner, M. E. ; Pawlita, M. ; Tommasino, M. ; Brennan, P. / Predictors of oropharyngeal cancer survival in Europe. In: Oral Oncology. 2018 ; Vol. 81. pp. 89-94.
@article{a3e5a3545d0d4e8a9032c13e13dfaef4,
title = "Predictors of oropharyngeal cancer survival in Europe",
abstract = "Objectives: HPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative patients. Currently, strategies for treatment de-escalation are based on HPV status, smoking history and disease stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in OPC survival remains uncertain. Materials and Methods: We examined factors associated with OPC outcome in 321 patients recruited in a large European multi-center study. Seropositivity for HPV16 E6 was used as a marker of HPV16 positive cancer. Hazard ratios (HR) and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential confounders. Results: Overall 5-year survival following OPC diagnosis was 50{\%}. HPV16-positive OPC cases were at significantly lower risk of death (aHR = 0.51, 95{\%} CI: 0.32–0.80). A significant effect on OPC survival was apparent for female sex (aHR 0.50: 95{\%} CI: 0.29–0.85) and being underweight at diagnosis (aHR: 2.41, 95{\%} CI: 1.38–4.21). A 10 pack year smoking history was not associated with overall survival. Higher stage at diagnosis appeared as the only factor significantly associated with OPC recurrence (aHR: 4.88, 95{\%} CI: 2.12–11.21). Conclusion: This study confirms that HPV16 status is an independent prognostic factor for OPC survival while female sex lowers risk of death and being underweight at diagnosis increases the risk of death. Smoking was not an independent predictor of OPC survival.",
keywords = "Body mass index, Gender, Head and neck cancer, HPV16, Oropharynx cancer, Survival, Tobacco",
author = "D. Anantharaman and A. Billot and T. Waterboer and T. Gheit and B. Abedi-Ardekani and P. Lagiou and A. Lagiou and W. Ahrens and I. Holc{\'a}tov{\'a} and F. Merletti and K. Kjaerheim and J. Polesel and L. Simonato and L. Alemany and {Mena Cervigon}, M. and Macfarlane, {T. V.} and A. Znaor and Thomson, {P. J.} and M. Robinson and C. Canova and Conway, {D. I.} and S. Wright and Healy, {C. M.} and Toner, {M. E.} and M. Pawlita and M. Tommasino and P. Brennan",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.oraloncology.2018.04.016",
language = "English",
volume = "81",
pages = "89--94",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Predictors of oropharyngeal cancer survival in Europe

AU - Anantharaman, D.

AU - Billot, A.

AU - Waterboer, T.

AU - Gheit, T.

AU - Abedi-Ardekani, B.

AU - Lagiou, P.

AU - Lagiou, A.

AU - Ahrens, W.

AU - Holcátová, I.

AU - Merletti, F.

AU - Kjaerheim, K.

AU - Polesel, J.

AU - Simonato, L.

AU - Alemany, L.

AU - Mena Cervigon, M.

AU - Macfarlane, T. V.

AU - Znaor, A.

AU - Thomson, P. J.

AU - Robinson, M.

AU - Canova, C.

AU - Conway, D. I.

AU - Wright, S.

AU - Healy, C. M.

AU - Toner, M. E.

AU - Pawlita, M.

AU - Tommasino, M.

AU - Brennan, P.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Objectives: HPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative patients. Currently, strategies for treatment de-escalation are based on HPV status, smoking history and disease stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in OPC survival remains uncertain. Materials and Methods: We examined factors associated with OPC outcome in 321 patients recruited in a large European multi-center study. Seropositivity for HPV16 E6 was used as a marker of HPV16 positive cancer. Hazard ratios (HR) and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential confounders. Results: Overall 5-year survival following OPC diagnosis was 50%. HPV16-positive OPC cases were at significantly lower risk of death (aHR = 0.51, 95% CI: 0.32–0.80). A significant effect on OPC survival was apparent for female sex (aHR 0.50: 95% CI: 0.29–0.85) and being underweight at diagnosis (aHR: 2.41, 95% CI: 1.38–4.21). A 10 pack year smoking history was not associated with overall survival. Higher stage at diagnosis appeared as the only factor significantly associated with OPC recurrence (aHR: 4.88, 95% CI: 2.12–11.21). Conclusion: This study confirms that HPV16 status is an independent prognostic factor for OPC survival while female sex lowers risk of death and being underweight at diagnosis increases the risk of death. Smoking was not an independent predictor of OPC survival.

AB - Objectives: HPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative patients. Currently, strategies for treatment de-escalation are based on HPV status, smoking history and disease stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in OPC survival remains uncertain. Materials and Methods: We examined factors associated with OPC outcome in 321 patients recruited in a large European multi-center study. Seropositivity for HPV16 E6 was used as a marker of HPV16 positive cancer. Hazard ratios (HR) and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential confounders. Results: Overall 5-year survival following OPC diagnosis was 50%. HPV16-positive OPC cases were at significantly lower risk of death (aHR = 0.51, 95% CI: 0.32–0.80). A significant effect on OPC survival was apparent for female sex (aHR 0.50: 95% CI: 0.29–0.85) and being underweight at diagnosis (aHR: 2.41, 95% CI: 1.38–4.21). A 10 pack year smoking history was not associated with overall survival. Higher stage at diagnosis appeared as the only factor significantly associated with OPC recurrence (aHR: 4.88, 95% CI: 2.12–11.21). Conclusion: This study confirms that HPV16 status is an independent prognostic factor for OPC survival while female sex lowers risk of death and being underweight at diagnosis increases the risk of death. Smoking was not an independent predictor of OPC survival.

KW - Body mass index

KW - Gender

KW - Head and neck cancer

KW - HPV16

KW - Oropharynx cancer

KW - Survival

KW - Tobacco

UR - http://www.scopus.com/inward/record.url?scp=85046774488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046774488&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2018.04.016

DO - 10.1016/j.oraloncology.2018.04.016

M3 - Article

AN - SCOPUS:85046774488

VL - 81

SP - 89

EP - 94

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -